The reactivation of RAS-MAPK signaling by 10 genetic alterations affecting the RAS-RAF-MEK-ERK pathway has been described in an NSCLC patient with acquired adagrasib resistance [204]. Here, MAP2K7 is linked to non-small cell lung carcinoma.